{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:24:26Z","timestamp":1791329066114,"version":"4.3.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.pharma.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T15:17:05Z","timestamp":1358954225000},"page":"84-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quel avenir en th\u00e9rapeutique cardiovasculaire pour le monoxyde d\u2019azote et ses d\u00e9riv\u00e9s\u00a0?"],"prefix":"10.1016","volume":"71","author":[{"given":"M.","family":"Parent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2012.12.004_bib0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/bj3570593","article-title":"Nitric oxide synthases: structure, function and inhibition","volume":"357","author":"Alderton","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yjmcc.2011.09.006","article-title":"Sub-cellular targeting of constitutive NOS in health and disease","volume":"52","author":"Zhang","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0015","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.112.266395","article-title":"Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype","volume":"111","author":"Sansbury","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2012.12.004_bib0465","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3858\/emm.2012.44.10.068","article-title":"Increased arginase II activity contributes to endothelial dysfunction through endothelial nitric oxide synthase uncoupling in aged mice","volume":"44","author":"Shin","year":"2012","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.pharma.2012.12.004_bib0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2012.07.006","article-title":"Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl) thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine","volume":"55","author":"Annedi","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharma.2012.12.004_bib0030","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbrc.2012.03.039","article-title":"nNOS downregulation attenuates neuronal apoptosis by inhibiting nNOS-GluR6\u00a0interaction and GluR6\u00a0nitrosylation in cerebral ischemic reperfusion","volume":"420","author":"Di","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharma.2012.12.004_bib0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pharmthera.2011.11.005","article-title":"The PSD-95\/nNOS complex: new drugs for depression","volume":"133","author":"Doucet","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharma.2012.12.004_bib0040","doi-asserted-by":"crossref","first-page":"823902","DOI":"10.1155\/2012\/823902","article-title":"Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease","volume":"2012","author":"Koppula","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharma.2012.12.004_bib0470","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.resp.2012.08.015","article-title":"Effects of corticosteroid, montelukast and iNOS inhibition on distal lung with chronic inflammation","volume":"185","author":"De Souza","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0050","doi-asserted-by":"crossref","first-page":"14007","DOI":"10.1073\/pnas.1211509109","article-title":"Chronic epithelial NF-\u03baB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation","volume":"109","author":"Shaked","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2012.12.004_bib0055","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1463-1326.2012.01632.x","article-title":"Pancreatic \u03b2-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2\u00a0diabetes","volume":"14","author":"Muhammed","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharma.2012.12.004_bib0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/13543776.2011.556619","article-title":"Novel nitric oxide synthase inhibitors: a patent review","volume":"21","author":"Joubert","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.pharma.2012.12.004_bib0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/niox.1996.0112","article-title":"A tutorial on the diffusibility and reactivity of free nitric oxide","volume":"1","author":"Lancaster","year":"1997","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharma.2012.12.004_bib0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0031-6997(24)01457-1","article-title":"Guanylyl cyclases and signaling by cyclic GMP","volume":"52","author":"Lucas","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharma.2012.12.004_bib0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-540-68964-5_2","article-title":"Biochemistry of soluble guanylate cyclase","volume":"191","author":"Derbyshire","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.bbagen.2011.03.008","article-title":"Regulation of mitochondrial processes by protein S-nitrosylation","volume":"1820","author":"Piantadosi","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharma.2012.12.004_bib0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/BJ20100633","article-title":"Identification of S-nitrosated mitochondrial proteins by S-nitrosothiol difference in gel electrophoresis (SNO-DIGE): implications for the regulation of mitochondrial function by reversible S-nitrosation","volume":"430","author":"Chouchani","year":"2010","journal-title":"Biochem J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nature11626","article-title":"Endothelial cell expression of haemoglobin \u03b1 regulates nitric oxide signaling","volume":"491","author":"Straub","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2012.12.004_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharma.2012.12.004_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12013-011-9179-3","article-title":"Nitric oxide inhibits vascular smooth cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10","volume":"60","author":"Tsihlis","year":"2011","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.pharma.2012.12.004_bib0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.blre.2011.03.002","article-title":"Platelets at work in primary hemostasis","volume":"25","author":"Broos","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharma.2012.12.004_bib0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1113\/expphysiol.1997.sp004029","article-title":"Role of nitric oxide in regulation of leucocyte-endothelial cell interactions","volume":"82","author":"Hickey","year":"1997","journal-title":"Exp Physiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0115","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.004721","article-title":"Site-mapping of in vitro S-nitrosation in cardiac mitochondria: implications for cardioprotection","volume":"10","author":"Murray","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.pharma.2012.12.004_bib0120","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMra051884","article-title":"Inhaled nitric oxide therapy in adults","volume":"353","author":"Griffiths","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2012.12.004_bib0125","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1161\/01.RES.66.6.1561","article-title":"Control of coronary vascular tone by nitric oxide","volume":"66","author":"Kelm","year":"1990","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2012.12.004_bib0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1042\/cs0980507","article-title":"S-nitrosothiols: a class of nitric oxide-donor drugs","volume":"98","author":"Al-Sa\u2019doni","year":"2000","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharma.2012.12.004_bib0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","article-title":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial","volume":"359","author":"IONA Study Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2012.12.004_bib0140","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","article-title":"Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology","volume":"27","author":"Fox","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1099-1557(199905\/06)8:3<197::AID-PDS422>3.0.CO;2-T","article-title":"Safety profile of nicorandil-prescription-event monitoring (PEM) study","volume":"8","author":"Dunn","year":"1999","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pharma.2012.12.004_bib0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1308\/003588412X13171221501573","article-title":"Nicorandil associated anal ulcers: an estimate of incidence","volume":"94","author":"Colvin","year":"2012","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.pharma.2012.12.004_bib0155","first-page":"59","article-title":"Some account of a disorder of the breast","volume":"2","author":"Heberden","year":"1772","journal-title":"Med Trans Coll Phsns Lond"},{"key":"10.1016\/j.pharma.2012.12.004_bib0160","unstructured":"OMS. Fact sheet No.\u00a0310: the 10\u00a0leading causes of death by broad income group (2008). 2011."},{"key":"10.1016\/j.pharma.2012.12.004_bib0165","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.107.187930","volume":"116","author":"Fraker","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2012.12.004_bib0170","doi-asserted-by":"crossref","first-page":"13592","DOI":"10.3390\/molecules171113592","article-title":"Ivabradine: an intelligent drug for the treatment of ischemic heart disease","volume":"17","author":"Riccioni","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.pharma.2012.12.004_bib0175","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1440-1681.2000.03240.x","article-title":"A short history of nitroglycerine and nitric oxide in pharmacology and physiology","volume":"27","author":"Marsh","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0140-6736(02)42573-1","article-title":"Nitroglycerin as a remedy for angina pectoris","volume":"80\u20131","author":"Murrel","year":"1879","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2012.12.004_bib0185","doi-asserted-by":"crossref","first-page":"8306","DOI":"10.1073\/pnas.122225199","article-title":"Identification of the enzymatic mechanism of nitroglycerin bioactivation","volume":"99","author":"Chen","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2012.12.004_bib0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0014-5793(99)00612-2","article-title":"Isoforms of cytochrome P450\u00a0on organic nitrate-derived nitric oxide release in human heart vessels","volume":"452","author":"Minamiyama","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharma.2012.12.004_bib0195","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/01.CIR.87.5.1461","article-title":"The nitrovasodilators. New ideas about old drugs","volume":"87","author":"Harrison","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2012.12.004_bib0200","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.RES.68.3.847","article-title":"Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin","volume":"68","author":"Kurz","year":"1991","journal-title":"Circ Res"},{"key":"10.1016\/j.pharma.2012.12.004_bib0205","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0735-1097(91)90686-4","article-title":"The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders","volume":"18","author":"Stamler","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0210","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.1905.92500480026001f","article-title":"Tolerance to nitroglycerin","volume":"XLIV","author":"Stewart","year":"1905","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2012.12.004_bib0215","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/oxfordjournals.eurheartj.a059425","article-title":"Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule","volume":"10","author":"Ferratini","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0220","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF00053031","article-title":"Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure","volume":"10","author":"Thadani","year":"1997","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharma.2012.12.004_bib0225","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0735-1097(01)01238-4","article-title":"Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets","volume":"37","author":"Chirkov","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pharmthera.2007.06.012","article-title":"Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier","volume":"116","author":"Chirkov","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharma.2012.12.004_bib0235","doi-asserted-by":"crossref","first-page":"R1014","DOI":"10.1152\/ajpregu.00124.2004","article-title":"Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology","volume":"287","author":"Li","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0240","doi-asserted-by":"crossref","first-page":"21664","DOI":"10.1016\/S0021-9258(17)31857-4","article-title":"Inactivation of human aldehyde dehydrogenase by isosorbide dinitrate","volume":"269","author":"Mukerjee","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharma.2012.12.004_bib0245","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1050-1738(97)00088-1","article-title":"NADH\/NADPH oxidase and vascular function","volume":"7","author":"Griendling","year":"1997","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharma.2012.12.004_bib0250","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/CIRCULATIONAHA.110.981407","article-title":"Nitrate therapy: new aspects concerning molecular action and tolerance","volume":"123","author":"M\u00fcnzel","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2012.12.004_bib0255","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1124\/mol.108.052142","article-title":"Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation","volume":"75","author":"Mayer","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/niox.2001.0394","article-title":"Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases","volume":"6","author":"Maxwell","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharma.2012.12.004_bib0265","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","article-title":"Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease","volume":"101","author":"Sch\u00e4chinger","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2012.12.004_bib0270","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2006.10.074","article-title":"Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism","volume":"49","author":"Thomas","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0275","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacc.2008.04.019","article-title":"Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs","volume":"52","author":"Gori","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0280","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-8703(99)70163-8","article-title":"Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group","volume":"138","author":"Nakamura","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0285","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1253\/circj.71.301","article-title":"Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis","volume":"71","author":"Kojima","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0290","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/eurheartj\/ehp457","article-title":"Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693\u00a0patients in the Global Registry of Acute Coronary Events","volume":"31","author":"Ambrosio","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharma.2012.12.004_bib0295","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1161\/CIRCULATIONAHA.104.515445","article-title":"Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests","volume":"111","author":"Jneid","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2012.12.004_bib0300","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/ars.2007.1679","article-title":"Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities","volume":"10","author":"Otani","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pharma.2012.12.004_bib0305","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cardiores.2003.09.025","article-title":"Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury","volume":"60","author":"Hausenloy","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharma.2012.12.004_bib0310","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cvr\/27.4.578","article-title":"Molecular adaptation of cellular defences following preconditioning of the heart by repeated ischaemia","volume":"27","author":"Das","year":"1993","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharma.2012.12.004_bib0315","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/jmcc.2001.1516","article-title":"Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction","volume":"34","author":"Sasaki","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0320","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2165\/11592300-000000000-00000","article-title":"Use of nicorandil in cardiovascular disease and its optimization","volume":"71","author":"Horinaka","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2012.12.004_bib0325","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2125.2007.02864.x","article-title":"Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight","volume":"64","author":"Gori","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0330","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.freeradbiomed.2011.04.042","article-title":"Inorganic nitrite therapy: historical perspective and future directions","volume":"51","author":"Kevil","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharma.2012.12.004_bib0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.niox.2009.11.001","article-title":"Clinical translation of nitrite therapy for cardiovascular diseases","volume":"22","author":"Calvert","year":"2010","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharma.2012.12.004_bib0340","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1021\/cr000028t","article-title":"Chemistry of the nitric oxide-releasing diazeniumdiolate (nitrosohydroxylamine) functional group and its oxygen derivatives","volume":"102","author":"Hrabie","year":"2002","journal-title":"Chem Rev"},{"key":"10.1016\/j.pharma.2012.12.004_bib0345","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/jm00115a013","article-title":"Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects","volume":"34","author":"Maragos","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharma.2012.12.004_bib0350","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(87)90392-X","article-title":"Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin","volume":"144","author":"Kowaluk","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0355","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3565(25)23090-7","article-title":"Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure","volume":"256","author":"Bauer","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2012.12.004_bib0360","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0022-3565(25)11228-7","article-title":"Lack of tolerance to a 24-hour infusion of S-nitroso N-acetylpenicillamine (SNAP) in conscious rabbits","volume":"260","author":"Shaffer","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2012.12.004_bib0365","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0014-2999(00)00777-9","article-title":"Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries","volume":"408","author":"Miller","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0370","doi-asserted-by":"crossref","first-page":"e43190","DOI":"10.1371\/journal.pone.0043190","article-title":"Endothelial \u03b3-glutamyltransferase contributes to the vasorelaxant effect of S-nitrosoglutathione in rat aorta","volume":"7","author":"Dahboul","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2012.12.004_bib0375","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/cvr\/28.5.691","article-title":"Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation","volume":"28","author":"De Belder","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharma.2012.12.004_bib0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2125.1995.tb04545.x","article-title":"Systemic effects of S-nitroso-glutathione in the human following intravenous infusion","volume":"40","author":"Ramsay","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0385","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0022-3565(25)09496-0","article-title":"Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery","volume":"273","author":"MacAllister","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2012.12.004_bib0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.niox.2004.04.008","article-title":"Bound NO in human red blood cells: fact or artifact","volume":"10","author":"Bryan","year":"2004","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharma.2012.12.004_bib0395","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1742-2094-8-78","article-title":"S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats","volume":"8","author":"Khan","year":"2011","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.pharma.2012.12.004_bib0400","first-page":"383","article-title":"Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion","volume":"30","author":"Sakakima","year":"2012","journal-title":"Restor Neurol Neurosci"},{"key":"10.1016\/j.pharma.2012.12.004_bib0405","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.yjmcc.2009.01.012","article-title":"In vivo cardioprotection by S-nitroso-2-mercaptopropionyl glycine","volume":"46","author":"Nadtochiy","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0410","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1073\/pnas.0903250106","article-title":"A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury","volume":"106","author":"Prime","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2012.12.004_bib0475","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2174\/138161213804143635","article-title":"S-nitrosation\/denitrosation in cardiovascular pathologies: facts and concepts for the rational design of S-nitrosothiols","volume":"19","author":"Gaucher","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharma.2012.12.004_bib0480","first-page":"31","article-title":"A complete physicochemical identity card of S-nitrosoglutathione","volume":"9","author":"Parent","year":"2013","journal-title":"Curr Pharm Anal"},{"key":"10.1016\/j.pharma.2012.12.004_bib0425","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.biomaterials.2004.06.006","article-title":"Polymers incorporating nitric oxide-releasing\/generating substances for improved biocompatibility of blood-contacting medical devices","volume":"26","author":"Frost","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharma.2012.12.004_bib0430","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cbf.1738","article-title":"In vitro evaluation of the safe margin, antithrombotic and antiproliferative actions for the treatment of restenosis: nitric oxide donor and polymers","volume":"29","author":"Sorragi","year":"2011","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.pharma.2012.12.004_bib0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11914-011-0087-7","article-title":"Nitric oxide donors for the treatment of osteoporosis","volume":"10","author":"Jamal","year":"2012","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pharma.2012.12.004_bib0440","first-page":"CD007444","article-title":"Nitric oxide donors for cervical ripening in first-trimester surgical abortion","volume":"12","author":"Promsonthi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharma.2012.12.004_bib0445","first-page":"93","article-title":"The role of nitric oxide donors in treating cerebral vasospasm after subarachnoid hemorrhage","volume":"110","author":"Fathi","year":"2011","journal-title":"Acta Neurochir Suppl"},{"key":"10.1016\/j.pharma.2012.12.004_bib0450","first-page":"909","article-title":"Nitric oxide donors: novel cancer therapeutics","volume":"33","author":"Huerta","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharma.2012.12.004_bib0455","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/SHK.0b013e3181777eef","article-title":"Nitric oxide donors in sepsis: a systematic review of clinical and in vivo preclinical data","volume":"30","author":"Lamontagne","year":"2008","journal-title":"Shock"},{"key":"10.1016\/j.pharma.2012.12.004_bib0460","first-page":"642","article-title":"Nitric oxide donors, a new treatment for insulin resistance, metabolic syndrome and diabetes?","volume":"124","author":"Jayet","year":"2004","journal-title":"Rev Med Suisse Romande"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450913000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450913000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:30:45Z","timestamp":1757719845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450913000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0003450913000023"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2012.12.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quel avenir en th\u00e9rapeutique cardiovasculaire pour le monoxyde d\u2019azote et ses d\u00e9riv\u00e9s\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2012.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}